Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epithelial-Mesenchymal Transition (EMT) and Cancer Metastasis Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VIM drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VIM Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for binding assays. |
View VIM Products |
| Gene Delivery | VIM Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-surface expression studies. |
View VIM Products |
| Benchmark Ab | Anti-VIM Recombinant Antibody Recombinant positive control for assay validation and immunohistochemistry. |
View VIM Products |
| Validator | VIM siRNA Set For knockdown verification in EMT-induced cell models. |
View VIM Products |
| Related Target A | CDH2 (N-Cadherin) Key mesenchymal marker co-expressed during EMT-mediated metastasis and drug resistance. |
View CDH2 Products |
| Related Target B | TGFB1 (TGF-beta 1) Primary physiological inducer of EMT and cell-surface vimentin upregulation. |
View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cell-Surface Vimentin (CSV) targeting | Lentivirus-mediated stable cell lines preserve native conformational presentation of surface vimentin. |
| Polymerization state interference | High-purity recombinant proteins with strictly verified monomeric/oligomeric states. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live VIM R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VIM therapeutics is intensifying, with major players shifting focus from traditional intracellular markers to Cell-Surface Vimentin (CSV) in oncology. As first-generation therapies reach the clinic, the next wave of R&D is targeting CSV-specific monoclonal antibodies, drug conjugates (ADCs), and small-molecule inhibitors designed to disrupt the vimentin intermediate filament network in metastatic cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (anti-CSV) | Academic Medical Centers, Biotech Startups | Metastatic Solid Tumors, Sarcomas | Cell-surface binding assays (Need VIM Lentivirus for stable cell lines) |
| Small Molecule Inhibitor | Pharmaceutical Developers | Drug-Resistant Cancers, Fibrosis | In vitro binding & polymerization assays (Need High-Purity Recombinant VIM) |
| siRNA / Therapeutics | RNAi Therapeutics Specialists | Advanced Epithelial Cancers | In vitro knockdown validation (Need Validated VIM siRNA Sets) |